Glenmark Pharmaceuticals’ subsidiary--Glenmark Therapeutics Inc., USA has launched Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX Powder for Solution, 17 grams of Bayer HealthCare LLC. Glenmark’s Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) is only marketed for the indications listed in Glenmark’s approved drug facts label.
According to Nielsen syndicated data for the latest 52 weeks’ period ending February 22, 2025, the MiraLAX Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
